Related Experiment Videos
The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells
T Florio1, C Rim, R E Hershberger
1Vollum Institute for Advanced Biomedical Research, Oregon Health Sciences University, Portland 97201.
Abstract:
Somatostatin receptors are abundantly expressed on a variety of human endocrine and epithelial tumors. The ability of these receptors to couple to effector pathways that inhibit the growth of these tumor cells has prompted the use of somatostatin agonists in the treatment of human neoplasms. It has been demonstrated that somatostatin stimulates a phosphotyrosine phosphatase in human tumor cells through a receptor-mediated process. This stimulation may counteract the growth-promoting properties of growth factors and the receptor tyrosine kinases that they activate. The recent cloning and characterization of distinct somatostatin receptor subtypes raise the possibility that different receptor subtypes mediate distinct effector pathways. To determine whether cloned somatostatin receptors could mediate coupling to phosphotyrosine phosphotyrosine phosphatase activity, we examined phosphatase activity after somatotostatin activation of the rat somatostatin receptors SSTR1 and SSTR2 after their stable expression in heterologous Chinese Hamster Ovary (CHO-K1) cells. We found that stimulation of SSTR1 cells was capable of increasing phosphotyrosine phosphatase activity, despite the coupling of both receptors to the inhibition of adenylyl cyclase in these cells. This activation was characterized by an EC50 of 70 nM and was sensitive to pertussis toxin. In addition, we demonstrate that activation of phosphotyrosine phosphatase activity in pituitary cell lines correlates with the endogenous expression of the SSTR1 gene within these cells.
Insights
Somatostatin receptor subtype 1 (SSTR1) activates phosphotyrosine phosphatase, counteracting tumor cell growth. This finding offers new therapeutic targets for neoplasms expressing somatostatin receptors.
Area of Science:
- Molecular Endocrinology
- Signal Transduction
- Oncology
Background:
- Somatostatin receptors are prevalent in human endocrine and epithelial tumors.
- Somatostatin agonists are used to treat neoplasms by inhibiting tumor cell growth.
- Somatostatin activates phosphotyrosine phosphatase, potentially counteracting growth factor signaling.
Purpose of the Study:
- To investigate if cloned somatostatin receptors mediate coupling to phosphotyrosine phosphatase activity.
- To determine the specific role of somatostatin receptor subtypes in phosphatase activation.
Main Methods:
- Stable expression of rat somatostatin receptors SSTR1 and SSTR2 in Chinese Hamster Ovary (CHO-K1) cells.
- Measurement of phosphotyrosine phosphatase activity following somatostatin stimulation.
- Assessment of receptor coupling to adenylyl cyclase inhibition.
- Pertussis toxin sensitivity assay.
Main Results:
- Somatostatin stimulation of SSTR1-expressing cells increased phosphotyrosine phosphatase activity (EC50 = 70 nM).
- Both SSTR1 and SSTR2 coupled to adenylyl cyclase inhibition.
- Phosphatase activation by SSTR1 was sensitive to pertussis toxin.
- Endogenous SSTR1 expression in pituitary cell lines correlated with increased phosphotyrosine phosphatase activity.
Conclusions:
- Somatostatin receptor subtype 1 (SSTR1) can activate phosphotyrosine phosphatase.
- This SSTR1-mediated phosphatase activation represents a distinct effector pathway.
- SSTR1's role in phosphatase activation may contribute to its anti-neoplastic effects.